New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections

European Journal of Cancer

Volumn 38, Issue 17, 2002, Pages 2229-2242

  Von Knebel Doeberitz, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cervical cancer screening; Cervical dysplasia; E6; E7; HPV; Molecular markers

Indexed keywords

BIOLOGICAL MARKER; CELL PROTEIN; GENE PRODUCT; MESSENGER RNA; PROTEIN P16;

AGE; CANCER SCREENING; CELL CYCLE; CELL DIVISION; CHEMICAL ANALYSIS; CHROMOSOME ABERRATION; DISEASE COURSE; DISEASE MARKER; EPITHELIUM CELL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REPLICATION; GENOMICS; GENOTOXICITY; HIGH RISK POPULATION; HISTOLOGY; HUMAN; INVASIVE CARCINOMA; MITOSIS SPINDLE; MOLECULAR BIOLOGY; ONCOGENE; PAPILLOMA VIRUS; PRECANCER; PRIORITY JOURNAL; REVIEW; SMEAR; UTERINE CERVIX DYSPLASIA; VIRUS GENE; VIRUS INFECTION;

EID: 0036850358     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00462-8     Document Type: Article

References (89)

1. Segnan N. Cervical cancer screening. Human benefits and human costs in the evaluation of screening programmes. Eur. J. Cancer. 30A:1994;873-875.
2. Papanicolaou G.N., Traut H.F. The diagnostic value of vaginal smears in carcinoma of the uterus. 1941. Arch. Pathol. Lab. Med. 121:1997;211-224.
3. Koss L.G. The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA. 261:1989;737-743.
4. Sasieni P.D., Cuzick J., Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br. J. Cancer. 73:1996;1001-1005.
5. Jones M.H., Jenkins D., Singer A. Regular audit of colposcopic biopsies from women with a mildly dyskaryotic or borderline cervical smear results in fewer cases of CINIII. Cytopathology. 7:1996;17-24.
6. Jones M.H., Singer A., Jenkins D. The mildly abnormal cervical smear. patient anxiety and choice of management J. R. Soc. Med. 89:1996;257-260.
7. Sherlaw-Johnson C., Gallivan S., Jenkins D., Jones M.H. Cytological screening and management of abnormalities in prevention of cervical cancer. an overview with stochastic modelling J. Clin. Pathol. 47:1994;430-435.
8. Walboomers J.M., Meijer C.J. Do HPV-negative cervical carcinomas exist? [editorial]. J. Pathol. 181:1997;253-254.
9. Munoz N. Human papillomavirus and cancer. the epidemiological evidence J. Clin. Virol. 19:2000;1-5.
10. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instability in colorectal cancers. Nature. 386:1997;623-627.
11. White A.E., Livanos E.M., Tlsty T.D. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev. 8:1994;666-677.
12. Duensing S., Munger K. Centrosome abnormalities, genomic instability and carcinogenic progression. Biochim. Biophys. Acta. 1471:2001;M81-M88.
13. von Knebel Doeberitz M., Oltersdorf T., Schwarz E., Gissmann L. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res. 48:1988;3780-3786.
14. zur Hausen H. Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin. Cancer Biol. 9:1999;405-411.
15. Koutsky L. Epidemiology of genital human papillomavirus infection. Am. J. Med. 102:1997;3-8.
16. Ho G.Y., Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338:1998;423-428.
17. Franco E.L., Villa L.L., Sobrinho J.P.et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J. Infect. Dis. 180:1999;1415-1423.
18. Solomon D., Schiffman M., Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance baseline results from a randomized trial. J. Natl. Cancer Inst. 93:2001;293-299.
19. Thomas D.B., Ray R.M., Kuypers J.et al. Human papillomaviruses and cervical cancer in Bangkok. III. The role of husbands and commercial sex workers. Am. J. Epidemiol. 153:2001;40-748.
20. Stoler M.H., Rhodes C.R., Whitbeck A., Wolinsky S.M., Chow L.T., Broker T.R. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol. 23:1992;117-128.
21. Durst M., Glitz D., Schneider A., Zur H.H. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia. analysis by in situ hybridization Virology. 189:1992;132-140.
22. Stevenson M., Hudson L.C., Burns J.E., Stewart R.L., Wells M., Maitland N.J. Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and virus DNA copy number during the progression of cervical intraepithelial neoplasia. J. Gen. Virol. 81:2000;1825-1832.
23. Doorbar J., Foo C., Coleman N.et al. Characterization of events during the late stages of HPV16 infection in vivo using high-affinity synthetic Fabs to E4. Virology. 238:1997;40-52.
24. Frattini M.G., Lim H.B., Doorbar J., Laimins L.A. Induction of human papillomavirus type 18 late gene expression and genomic amplification in organotypic cultures from transfected DNA templates. J. Virol. 71:1997;7068-7072.
25. Ambros R.A., Kurman R.J. Current concepts in the relationship of human papillomavirus infection to the pathogenesis and classification of precancerous squamous lesions of the uterine cervix. Semin. Diagn. Pathol. 7:1990;158-172.
26. Fletcher S., Norval M. On the nature of the deep cellular disturbances in human-papilloma-virus infection of the squamous cervical epithelium. Lancet. 2:1983;546-549.
27. zur Hausen H. Papillomaviruses causing cancer. evasion from host-cell control in early events in carcinogenesis J. Natl. Cancer Inst. 92:2000;690-698.
28. zur Hausen H. Intracellular surveillance of persisting viral infections. Human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet. 2:1986;489-491.
29. Stoler M.H., Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations. realistic estimates from the ASCUS-LSIL Triage Study JAMA. 285:2001;1500-1505.
30. Hsu E.M., McNicol P.J., Guijon F.B., Paraskevas M. Quantification of HPV-16 E6-E7 transcription in cervical intraepithelial neoplasia by reverse transcriptase polymerase chain reaction. Int. J. Cancer. 55:1993;397-401.
31. Grossman S.R., Mora R., Laimins L.A. Intracellular localization and DNA-binding properties of human papillomavirus type 18 E6 protein expressed with a baculovirus vector. J. Virol. 63:1989;366-374.
32. Selvey L.A., Dunn L.A., Tindle R.W., Park D.S., Frazer I.H. Human papillomavirus (HPV) type 18 E7 protein is a short-lived steroid-inducible phosphoprotein in HPV-transformed cell lines. J. Gen. Virol. 75(Pt 7):1994;1647-1653.
33. Nees M., van Wijngaarden E., Bakos E., Schneider A., Durst M. Identification of novel molecular markers which correlate with HPV-induced tumor progression. Oncogene. 16:1998;2447-2458.
34. Nees M., Geoghegan J.M., Hyman T., Frank S., Miller L., Woodworth C.D. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol. 75:2001;4283-4296.
35. Klaes R., Friedrich T., Spitkovsky D.et al. Overexpression of p16INK4a as specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer. 2000.
36. Sano T., Oyama T., Kashiwabara K., Fukuda T., Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am. J. Pathol. 153:1998;1741-1748.
37. Pan H., Griep A.E. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice. implications for tumor suppressor gene function in development Genes Dev. 8:1994;1285-1299.
38. Mantovani F., Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene. 20:2001;7874-7887.
39. Barbosa M.S., Lowy D.R., Schiller J.T. Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J. Virol. 63:1989;1404-1407.
40. Storey A., Massimi P., Dawson K., Banks L. Conditional immortalization of primary cells by human papillomavirus type 18 E6 and EJ-ras defines an E6 activity in G0/G1 phase which can be substituted for mutations in p53. Oncogene. 11:1995;653-661.
41. Munger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63:1989;4417-4421.
42. Durst M., Dzarlieva-Petrusevska R.T., Boukamp P., Fusenig N.E., Gissmann L. Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA. Oncogene. 1:1987;251-256.
43. Durst M., Seagon S., Wanschura S., Zur H.H., Bullerdiek J. Malignant progression of an HPV16-immortalized human keratinocyte cell line (HPKIA) in vitro. Cancer Genet. Cytogenet. 85:1995;105-112.
44. Song S., Pitot H.C., Lambert P.F. The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J. Virol. 73:1999;5887-5893.
45. Herber R., Liem A., Pitot H., Lambert P.F. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J. Virol. 70:1996;1873-1881.
46. Scheffner M. Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol. Ther. 78:1998;129-139.
47. Hengstermann A., Linares L.K., Ciechanover A., Whitaker N.J., Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc. Natl. Acad. Sci. USA. 98:2001;1218-1223.
48. Tlsty T.D., Briot A., Gualberto A.et al. Genomic instability and cancer. Mutat. Res. 337:1995;1-7.
49. Butz K., Shahabeddin L., Geisen C., Spitkovsky D., Ullmann A., Hoppe-Seyler F. Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene. 10:1995;927-936.
50. Pim D., Banks L. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene. 18:1999;7403-7408.
51. Pim D., Massimi P., Banks L. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene. 15:1997;257-264.
52. Frost M., Bobak J.B., Gianani R.et al. Localization of telomerase hTERT protein and hTR in benign mucosa, dysplasia, and squamous cell carcinoma of the cervix. Am. J. Clin. Pathol. 114:2000;726-734.
53. Jarboe E.A., Liaw K.L., Thompson L.C.et al. Analysis of telomerase as a diagnostic biomarker of cervical dysplasia and carcinoma. Oncogene. 21:2002;664-673.
54. Jarboe E.A., Liaw K.L., Thompson L.C.et al. Analysis of telomerase as a diagnostic biomarker of cervical dysplasia and carcinoma. Oncogene. 21:2002;664-673.
55. Vousden K.H. Human papillomavirus oncoproteins. Semin. Cancer Biol. 1:1990;415-424.
56. Vousden K.H., Jat P.S. Functional similarity between HPV16E7, SV40 large T and adenovirus E1a proteins. Oncogene. 4:1989;153-158.
57. Reinstein E., Scheffner M., Oren M., Ciechanover A., Schwartz A. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system. targeting via ubiquitination of the N-terminal residue Oncogene. 19:2000;5944-5950.
58. Stubenrauch F., Laimins L.A. Human papillomavirus life cycle. active and latent phases Semin.Cancer Biol. 9:1999;379-386.
59. Cheng S., Schmidt-Grimminger D.C., Murant T., Broker T.R., Chow L.T. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 9:1995;2335-2349.
60. Morris E.J., Dyson N.J. Retinoblastoma protein partners. Adv. Cancer Res. 82:2001;1-54.
61. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 12:1998;2245-2262.
62. Jian Y., Schmidt-Grimminger D.C., Chien W.M., Wu X., Broker T.R., Chow L.T. Post-transcriptional induction of p21cip1 protein by human papillomavirus E7 inhibits unscheduled DNA synthesis reactivated in differentiated keratinocytes. Oncogene. 17:1998;2027-2038.
63. Zwerschke W., Mannhardt B., Massimi P.et al. Allosteric activation of acid alpha-glucosidase by the human papillomavirus E7 protein. J. Biol. Chem. 275:2000;9534-9541.
64. Zwerschke W., Mazurek S., Massimi P., Banks L., Eigenbrodt E., Jansen-Durr P. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA. 96:1999;1291-1296.
65. Reshkin S.J., Bellizzi A., Caldeira S.et al. Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J. 14:2000;2185-2197.
66. Omigbodun A.O., Thomas J.O., Adewole I.F., Ogunlusi M.L. Triage of patients with abnormal cervical smears in the absence of colposcopy. Trop. Geogr. Med. 45:1993;157-158.
67. Duensing S., Duensing A., Flores E.R., Do A., Lambert P.F., Munger K. Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes. J. Virol. 75:2001;7712-7716.
68. Duensing S., Lee L.Y., Duensing A.et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc. Natl. Acad. Sci. USA. 97:2000;10002-10007.
69. Murray A.W. Cell cycle. Centrioles at the checkpoint. Science. 291:2001;1499-1502.
70. Duensing S., Duensing A., Crum C.P., Munger K. Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype. Cancer Res. 61:2001;2356-2360.
71. Nevins J.R. The Rb/E2F pathway and cancer. Hum. Mol. Genet. 10:2001;699-703.
72. Khleif S.N., DeGregori J., Yee C.L.et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc. Natl. Acad. Sci. USA. 93:1996;4350-4354.
73. Nakao Y., Yang X., Yokoyama M.et al. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br. J. Cancer. 75:1997;1410-1416.
74. Wong Y.F., Chung T.K., Cheung T.H.et al. p16INK4 and p15INK4B alterations in primary gynecologic malignancy. Gynecol. Oncol. 65:1997;319-324.
75. Hirama T., Miller C.W., Wilczynski S.P., Koeffler H.P. p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines. Mod. Pathol. 9:1996;26-31.
76. Kim J.W., Namkoong S.E., Ryu S.W.et al. Absence of p15INK4B and p16INK4A gene alterations in primary cervical carcinoma tissues and cell lines with human papillomavirus infection. Gynecol. Oncol. 70:1998;75-79.
77. Keating J.T., Ince T., Crum C.P. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv. Anat. Pathol. 8:2001;83-92.
78. Munger K., Basile J.R., Duensing S.et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene. 20:2001;7888-7898.
79. Bibbo M., Klump W.J., De Cecco J., Kovatich A.J. Procedure for immunocytochemial detection of P161INK4A antigen in thin-layer, liquid-based speciments. Acta Cytol. 46:2002;25-25.
80. Lazo P.A. The molecular genetics of cervical carcinoma. Br. J. Cancer. 80:1999;2008-2018.
81. Kessis T.D., Connolly D.C., Hedrick L., Cho K.R. Expression of HPV16 E6 or E7 increases integration of foreign DNA. Oncogene. 13:1996;427-431.
82. Jeon S., Allen-Hoffmann B.L., Lambert P.F. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 69:1995;2989-2997.
83. Jeon S., Lambert P.F. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs. implications for cervical carcinogenesis Proc. Natl. Acad. Sci. USA. 92:1995;1654-1658.
84. von Knebel Doeberitz M., Bauknecht T., Bartsch D., zur Hausen H. Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. Proc. Natl. Acad. Sci. USA. 88:1991;1411-1415.
85. von Knebel Doeberitz M., Rittmuller C., Aengeneyndt F., Jansen-Durr P., Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells. consequences for the phenotype and E6-p53 and E7-pRB interactions J. Virol. 68:1994;2811-2821.
86. Klaes R., Woerner S.M., Ridder R.et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 59:1999;6132-6136.
87. Luft F., Klaes R., Nees M.et al. Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer cells. Int. J. Cancer. 92:2001;9-17.
88. Reuter S., Bartelmann M., Vogt M.et al. APM-1, a novel human gene, identified by aberrant co-transcription with papillomavirus oncogenes in a cervical carcinoma cell line, encodes a BTB/POZ-zinc finger protein with growth inhibitory activity. EMBO J. 17:1998;215-222.
89. Wentzensen N., Ridder R., Klaes R., Vinokurova S., Schaefer U., Doeberitz M.K. Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions. Oncogene. 21:2002;419-426.